{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:55:05Z","timestamp":1788188105394,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41440-021-00700-7","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T04:02:39Z","timestamp":1626753759000},"page":"1261-1273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice"],"prefix":"10.1038","volume":"44","author":[{"given":"Masato","family":"Narita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Yokono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Senoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritomo","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Osanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"700_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Colvin MM, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776\u2013803.","journal-title":"J Am Coll Cardiol"},{"key":"700_CR2","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1053\/euhj.2000.2533","volume":"22","author":"A Mosterd","year":"2001","unstructured":"Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J. 2001;22:1318\u201327.","journal-title":"Eur Heart J"},{"key":"700_CR3","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0735-1097(99)00118-7","volume":"33","author":"RS Vasan","year":"1999","unstructured":"Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"700_CR4","doi-asserted-by":"publisher","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"292","author":"PK Mehta","year":"2007","unstructured":"Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82\u201397.","journal-title":"Am J Physiol Cell Physiol"},{"key":"700_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/FJC.0000000000000374","volume":"67","author":"T Tanno","year":"2016","unstructured":"Tanno T, Tomita H, Narita I, Kinjo T, Nishizaki K, Ichikawa H, et al. Olmesartan inhibits cardiac hypertrophy in mice overexpressing renin independently of blood pressure: its beneficial effects on ACE2\/Ang(1-7)\/Mas axis and NADPH oxidase expression. J Cardiovasc Pharmacol. 2016;67:503\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"700_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1160\/th14-03-0243","volume":"112","author":"S Antoniak","year":"2014","unstructured":"Antoniak S, Sparkenbaugh E, Pawlinski R. Tissue factor, protease activated receptors and pathologic heart remodelling. Thromb Haemost. 2014;112:893\u2013900.","journal-title":"Thromb Haemost"},{"key":"700_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.105.567297","volume":"113","author":"J Steffel","year":"2006","unstructured":"Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113:722\u201331.","journal-title":"Circulation"},{"key":"700_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.5551\/jat.30940","volume":"22","author":"K Tatsumi","year":"2015","unstructured":"Tatsumi K, Mackman N. Tissue factor and atherothrombosis. J Atheroscler Thromb. 2015;22:543\u20139.","journal-title":"J Atheroscler Thromb"},{"key":"700_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1160\/TH13-09-0730","volume":"111","author":"CT Esmon","year":"2014","unstructured":"Esmon CT. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost. 2014;111:625\u201333.","journal-title":"Thromb Haemost"},{"key":"700_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/01.ATV.0000251995.73307.2d","volume":"27","author":"K Hirano","year":"2007","unstructured":"Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27:27\u201336.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"700_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/mol.104.003103","volume":"67","author":"SF Steinberg","year":"2005","unstructured":"Steinberg SF. The cardiovascular actions of protease-activated receptors. Mol Pharmacol. 2005;67:2\u201311.","journal-title":"Mol Pharmacol"},{"key":"700_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1161\/HYPERTENSIONAHA.111.169417","volume":"58","author":"JL McLarty","year":"2011","unstructured":"McLarty JL, Melendez GC, Brower GL, Janicki JS, Levick SP. Tryptase\/Protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension. 2011;58:264\u201370.","journal-title":"Hypertension"},{"key":"700_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.thromres.2018.05.015","volume":"167","author":"MF Bode","year":"2018","unstructured":"Bode MF, Auriemma AC, Grover SP, Hisada Y, Rennie A, Bode WD, et al. The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction. Thromb Res. 2018;167:128\u201334.","journal-title":"Thromb Res"},{"key":"700_CR14","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.107.692764","volume":"116","author":"R Pawlinski","year":"2007","unstructured":"Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, et al. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation. 2007;116:2298\u2013306.","journal-title":"Circulation"},{"key":"700_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"700_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","volume":"3","author":"E Perzborn","year":"2005","unstructured":"Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939\u2013an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514\u201321.","journal-title":"J Thromb Haemost"},{"key":"700_CR17","doi-asserted-by":"publisher","first-page":"432080","DOI":"10.1155\/2011\/432080","volume":"2011","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm. 2011;2011:432080.","journal-title":"Mediators Inflamm"},{"key":"700_CR18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1536\/ihj.15-112","volume":"56","author":"T Hashikata","year":"2015","unstructured":"Hashikata T, Yamaoka-Tojo M, Namba S, Kitasato L, Kameda R, Murakami M, et al. Rivaroxaban inhibits angiotensin II-induced activation in cultured mouse cardiac fibroblasts through the modulation of NF-kappaB pathway. Int Heart J. 2015;56:544\u201350.","journal-title":"Int Heart J"},{"key":"700_CR19","doi-asserted-by":"publisher","first-page":"8248","DOI":"10.1073\/pnas.112222199","volume":"99","author":"KM Caron","year":"2002","unstructured":"Caron KM, James LR, Kim HS, Morham SG, Sequeira Lopez ML, Gomez RA, et al. A genetically clamped renin transgene for the induction of hypertension. Proc Natl Acad Sci USA. 2002;99:8248\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"key":"700_CR20","doi-asserted-by":"publisher","first-page":"e012195","DOI":"10.1161\/JAHA.119.012195","volume":"8","author":"H Ichikawa","year":"2019","unstructured":"Ichikawa H, Shimada M, Narita M, Narita I, Kimura Y, Tanaka M, et al. Rivaroxaban, a direct factor Xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway. J Am Heart Assoc. 2019;8:e012195.","journal-title":"J Am Heart Assoc"},{"key":"700_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1152\/physiolgenomics.00221.2004","volume":"20","author":"KM Caron","year":"2005","unstructured":"Caron KM, James LR, Lee G, Kim HS, Smithies O. Lifelong genetic minipumps. Physiol Genom. 2005;20:203\u20139.","journal-title":"Physiol Genom"},{"key":"700_CR22","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1073\/pnas.0307333101","volume":"101","author":"KM Caron","year":"2004","unstructured":"Caron KM, James LR, Kim HS, Knowles J, Uhlir R, Mao L, et al. Cardiac hypertrophy and sudden death in mice with a genetically clamped renin transgene. Proc Natl Acad Sci USA. 2004;101:3106\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"700_CR23","doi-asserted-by":"publisher","first-page":"e81733","DOI":"10.1371\/journal.pone.0081733","volume":"8","author":"S Antoniak","year":"2013","unstructured":"Antoniak S, Sparkenbaugh EM, Tencati M, Rojas M, Mackman N, Pawlinski R. Protease activated receptor-2 contributes to heart failure. PLoS ONE. 2013;8:e81733.","journal-title":"PLoS ONE"},{"key":"700_CR24","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1161\/01.RES.86.10.1054","volume":"86","author":"A Sabri","year":"2000","unstructured":"Sabri A, Muske G, Zhang H, Pak E, Darrow A, Andrade-Gordon P, et al. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res. 2000;86:1054\u201361.","journal-title":"Circ Res"},{"key":"700_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.pharmtox.45.120403.095802","volume":"45","author":"RD Brown","year":"2005","unstructured":"Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 2005;45:657\u201387.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"700_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","volume":"94","author":"S Patel","year":"2017","unstructured":"Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017;94:317\u201325.","journal-title":"Biomed Pharmacother"},{"key":"700_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/01.hjh.0000226182.60321.69","volume":"24","author":"DA Duprez","year":"2006","unstructured":"Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens. 2006;24:983\u201391.","journal-title":"J Hypertens"},{"key":"700_CR28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1253\/circj.CJ-14-1203","volume":"79","author":"T Ueda","year":"2015","unstructured":"Ueda T, Kawakami R, Nishida T, Onoue K, Soeda T, Okayama S, et al. Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin-angiotensin system inhibitors. Circ J. 2015;79:1307\u201314.","journal-title":"Circ J"},{"key":"700_CR29","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1161\/CIRCULATIONAHA.118.033544","volume":"138","author":"T Hara","year":"2018","unstructured":"Hara T, Phuong PT, Fukuda D, Yamaguchi K, Murata C, Nishimoto S, et al. Protease-activated receptor-2 plays a critical role in vascular inflammation and atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2018;138:1706\u201319.","journal-title":"Circulation"},{"key":"700_CR30","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1161\/01.ATV.21.6.1078","volume":"21","author":"T Sugano","year":"2001","unstructured":"Sugano T, Tsuji H, Masuda H, Nishimura H, Yoshizumi M, Kawano H, et al. Adrenomedullin inhibits angiotensin II-induced expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2001;21:1078\u201383.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"700_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1172\/JCI116234","volume":"91","author":"MB Taubman","year":"1993","unstructured":"Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation. J Clin Investig. 1993;91:547\u201352.","journal-title":"J Clin Investig"},{"key":"700_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0002-9440(10)64523-3","volume":"157","author":"DN M\u00fcller","year":"2000","unstructured":"M\u00fcller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F, et al. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol. 2000;157:111\u201322.","journal-title":"Am J Pathol"},{"key":"700_CR33","doi-asserted-by":"publisher","first-page":"23038","DOI":"10.1074\/jbc.M401376200","volume":"279","author":"J Ahamed","year":"2004","unstructured":"Ahamed J, Ruf W. Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J Biol Chem. 2004;279:23038\u201344.","journal-title":"J Biol Chem"},{"key":"700_CR34","doi-asserted-by":"publisher","first-page":"e015616","DOI":"10.1161\/JAHA.119.015616","volume":"9","author":"Y Yokono","year":"2020","unstructured":"Yokono Y, Hanada K, Narita M, Tatara Y, Kawamura Y, Miura N, et al. Blockade of PAR-1 signaling attenuates cardiac hypertrophy and fibrosis in renin-overexpressing hypertensive mice. J Am Heart Assoc. 2020;9:e015616.","journal-title":"J Am Heart Assoc"},{"key":"700_CR35","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/01.RES.0000035242.96310.45","volume":"91","author":"A Sabri","year":"2002","unstructured":"Sabri A, Short J, Guo J, Steinberg SF. Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Circ Res. 2002;91:532\u20139.","journal-title":"Circ Res"},{"key":"700_CR36","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1096\/fj.12-213496","volume":"26","author":"AN Snead","year":"2012","unstructured":"Snead AN, Insel PA. Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts. FASEB J. 2012;26:4540\u20137.","journal-title":"FASEB J"},{"key":"700_CR37","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2353\/ajpath.2010.091107","volume":"177","author":"K Borensztajn","year":"2010","unstructured":"Borensztajn K, Bresser P, van der Loos C, Bot I, van den Blink B, den Bakker MA, et al. Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis. Am J Pathol. 2010;177:2753\u201364.","journal-title":"Am J Pathol"},{"key":"700_CR38","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbrc.2016.03.094","volume":"473","author":"RQ He","year":"2016","unstructured":"He RQ, Tang XF, Zhang BL, Li XD, Hong MN, Chen QZ, et al. Protease-activated receptor 1 and 2 contribute to angiotensin II-induced activation of adventitial fibroblasts from rat aorta. Biochem Biophys Res Commun. 2016;473:517\u201323.","journal-title":"Biochem Biophys Res Commun"},{"key":"700_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2353\/ajpath.2008.070347","volume":"172","author":"K Borensztajn","year":"2008","unstructured":"Borensztajn K, Stiekema J, Nijmeijer S, Reitsma PH, Peppelenbosch MP, Spek CA. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol. 2008;172:309\u201320.","journal-title":"Am J Pathol"},{"key":"700_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1161\/01.RES.74.3.369","volume":"74","author":"KH Muntz","year":"1994","unstructured":"Muntz KH, Zhao M, Miller JC. Downregulation of myocardial beta-adrenergic receptors. Receptor subtype selectivity. Circ Res. 1994;74:369\u201375.","journal-title":"Circ Res"},{"key":"700_CR41","doi-asserted-by":"publisher","first-page":"915","DOI":"10.5551\/jat.48405","volume":"26","author":"J Liu","year":"2019","unstructured":"Liu J, Nishida M, Inui H, Chang J, Zhu Y, Kanno K, et al. Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction. J Atheroscler Thromb. 2019;26:915\u201330.","journal-title":"J Atheroscler Thromb"},{"key":"700_CR42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jjcc.2017.08.007","volume":"71","author":"H Kondo","year":"2018","unstructured":"Kondo H, Abe I, Fukui A, Saito S, Miyoshi M, Aoki K, et al. Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation. J Cardiol. 2018;71:310\u20139.","journal-title":"J Cardiol"},{"key":"700_CR43","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/sj.bjp.0707150","volume":"150","author":"E Ritchie","year":"2007","unstructured":"Ritchie E, Saka M, Mackenzie C, Drummond R, Wheeler-Jones C, Kanke T, et al. Cytokine upregulation of proteinase-activated-receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase beta in human endothelial cells. Br J Pharmacol. 2007;150:1044\u201354.","journal-title":"Br J Pharmacol"},{"key":"700_CR44","doi-asserted-by":"publisher","first-page":"L788","DOI":"10.1152\/ajplung.00226.2006","volume":"292","author":"R Ramachandran","year":"2007","unstructured":"Ramachandran R, Sadofsky LR, Xiao Y, Botham A, Cowen M, Morice AH, et al. Inflammatory mediators modulate thrombin and cathepsin-G signaling in human bronchial fibroblasts by inducing expression of proteinase-activated receptor-4. Am J Physiol Lung Cell Mol Physiol. 2007;292:L788\u201398.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"700_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1472-8206.2006.00418.x","volume":"20","author":"V Freund-Michel","year":"2006","unstructured":"Freund-Michel V, Frossard N. Inflammatory conditions increase expression of protease-activated receptor-2 by human airway smooth muscle cells in culture. Fundam Clin Pharmacol. 2006;20:351\u20137.","journal-title":"Fundam Clin Pharmacol"},{"key":"700_CR46","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/CIRCRESAHA.116.309538","volume":"119","author":"MC Woodall","year":"2016","unstructured":"Woodall MC, Woodall BP, Gao E, Yuan A, Koch WJ. Cardiac fibroblast GRK2 deletion enhances contractility and remodeling following ischemia\/reperfusion injury. Circ Res. 2016;119:1116\u201327.","journal-title":"Circ Res"},{"key":"700_CR47","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1096\/fj.03-0037fje","volume":"17","author":"T Hayashida","year":"2003","unstructured":"Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 2003;17:1576\u20138.","journal-title":"FASEB J"},{"key":"700_CR48","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.cellsig.2014.05.018","volume":"26","author":"X Liu","year":"2014","unstructured":"Liu X, Hubchak SC, Browne JA, Schnaper HW. Epidermal growth factor inhibits transforming growth factor-beta-induced fibrogenic differentiation marker expression through ERK activation. Cell Signal. 2014;26:2276\u201383.","journal-title":"Cell Signal"},{"key":"700_CR49","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1006\/bbrc.2001.4597","volume":"282","author":"A Kawabata","year":"2001","unstructured":"Kawabata A, Kuroda R, Nakaya Y, Kawai K, Nishikawa H, Kawao N. Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2. Biochem Biophys Res Commun. 2001;282:432\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"700_CR50","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1161\/01.CIR.99.19.2590","volume":"99","author":"C Cicala","year":"1999","unstructured":"Cicala C, Pinto A, Bucci M, Sorrentino R, Walker B, Harriot P, et al. Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. Circulation. 1999;99:2590\u20137.","journal-title":"Circulation"},{"key":"700_CR51","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000442415","volume":"52","author":"K Maruyama","year":"2015","unstructured":"Maruyama K, Kagota S, McGuire JJ, Wakuda H, Yoshikawa N, Nakamura K, et al. Enhanced nitric oxide synthase activation via protease-activated receptor 2 is involved in the preserved vasodilation in aortas from metabolic syndrome rats. J Vasc Res. 2015;52:232\u201343.","journal-title":"J Vasc Res"},{"key":"700_CR52","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1476-5381.2011.01356.x","volume":"164","author":"S Kagota","year":"2011","unstructured":"Kagota S, Chia E, McGuire JJ. Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice. Br J Pharmacol. 2011;164:358\u201371.","journal-title":"Br J Pharmacol"},{"key":"700_CR53","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","volume":"242","author":"T Hara","year":"2015","unstructured":"Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Nishimoto S, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis. 2015;242:639\u201346.","journal-title":"Atherosclerosis"},{"key":"700_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47474-0","volume":"9","author":"PT Pham","year":"2019","unstructured":"Pham PT, Fukuda D, Yagi S, Kusunose K, Yamada H, Soeki T, et al. Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice. Sci Rep. 2019;9:11206.","journal-title":"Sci Rep"},{"key":"700_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/srep43079","volume":"7","author":"CS Moran","year":"2017","unstructured":"Moran CS, Seto SW, Krishna SM, Sharma S, Jose RJ, Biros E, et al. Parenteral administration of factor Xa\/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis. Sci Rep. 2017;7:43079.","journal-title":"Sci Rep"},{"key":"700_CR56","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3389\/fphar.2017.00647","volume":"8","author":"P Zuo","year":"2017","unstructured":"Zuo P, Zuo Z, Zheng Y, Wang X, Zhou Q, Chen L, et al. Protease-activated receptor-2 deficiency attenuates atherosclerotic lesion progression and instability in apolipoprotein E-deficient mice. Front Pharmacol. 2017;8:647.","journal-title":"Front Pharmacol"},{"key":"700_CR57","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.111.172700","volume":"57","author":"M Kurdi","year":"2011","unstructured":"Kurdi M, Booz GW. New take on the role of angiotensin II in cardiac hypertrophy and fibrosis. Hypertension. 2011;57:1034\u20138.","journal-title":"Hypertension"},{"key":"700_CR58","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1161\/HYPERTENSIONAHA.109.140608","volume":"55","author":"R Zhang","year":"2010","unstructured":"Zhang R, Zhang YY, Huang XR, Wu Y, Chung AC, Wu EX, et al. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension. 2010;55:953\u201360.","journal-title":"Hypertension"},{"key":"700_CR59","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1161\/HYPERTENSIONAHA.109.135715","volume":"55","author":"N Ardanaz","year":"2010","unstructured":"Ardanaz N, Yang XP, Cifuentes ME, Haurani MJ, Jackson KW, Liao TD, et al. Lack of glutathione peroxidase 1 accelerates cardiac-specific hypertrophy and dysfunction in angiotensin II hypertension. Hypertension. 2010;55:116\u201323.","journal-title":"Hypertension"},{"key":"700_CR60","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa032566","volume":"350","author":"MR Zile","year":"2004","unstructured":"Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure\u2013abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953\u20139.","journal-title":"N Engl J Med"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00700-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T23:27:31Z","timestamp":1633390051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00700-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1038\/s41440-021-00700-7","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"3 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HT received a scholarship or donation from Boehringer Ingelheim, Bayer, Daiichi-Sankyo, and Pfizer and speakers\u2019 bureau\/honorarium agreements from Boehringer Ingelheim, Bayer, and Daiichi-Sankyo. KO received speakers\u2019 bureau\/honorarium agreements from Daiichi-Sankyo, Boehringer Ingelheim, and Bayer. The remaining authors have no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}